2026 Interim report
Filed with HKEX · Stock code 2335 · · 82 pages · English and Chinese
王冰博士（主席） Yu Weiping博士 非執行董事 王梅博士游向東先生宋高廣博士王娜禕博士 獨立非執行董事 相里六續博士張文強先生王開峰先生 審計委員會 張文強先生（主席）王開峰先生王梅博士 提名委員會 王冰博士（主席）王梅博士張文強先生相里六續博士王開峰先生 薪酬委員會 相里六續博士（主席）王冰博士王開峰先生 授權代表 王冰博士陳綺藍女士 BOARD OF DIRECTORS Executive Directors Dr. Wang Bing (王冰) (Chairman) Dr. Yu Weiping Non-executive Directors Dr. Wang Mei (王梅) Mr. You Xiangdong (游向東) Dr. Song Gaoguang (宋高廣) Dr. Wang Nayi (王娜禕) Independent Non-executive Direct
Shaanxi Micot Pharmaceutical Technology Co., Ltd. on 6ix
Earlier from Shaanxi Micot Pharmaceutical Technology
- Announcement of allotment results
- List of directors and their roles and functions
- Documents on Display
Later from Shaanxi Micot Pharmaceutical Technology
- Notification letter to non-registered shareholders and reply form
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Proposed adoption of the h share incentive scheme and proposed general mandate to repurchase h shares
- Proposed general mandate to repurchase h shares and notice of extraordinary general meeting
- Notice of extraordinary general meeting
Follow Shaanxi Micot Pharmaceutical Technology into a list and get an email when it puts out news.
Follow Shaanxi Micot Pharmaceutical Technology